Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Cloudbreak Therapeutics LLC has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. Both of these actions are assigned to a single examiner, HUANG, GIGI GEORGIANA. This concentration means 1 distinct examiner manages the entirety of the company's current pending workload. Such a centralized prosecution strategy can lead to high consistency in how the company's technology is interpreted across its pending applications.
The portfolio is currently active in 1 distinct art unit. HUANG, GIGI GEORGIANA is identified as the busiest examiner with 2 pending actions, representing a situation where all active matters are overseen by the same individual. This high level of concentration under 1 distinct examiner and 1 distinct art unit means that the examiner's perspective will be the deciding factor for all current pending actions. Practitioners should focus on building a consistent rapport with this single examiner to manage the portfolio effectively.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUANG, GIGI GEORGIANA | 2 | 31.8% | +30.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17640889 | METHODS FOR ALLEVIATING PTERYGIUM-ASSOCIATED WORRY ABOUT EYE APPEARANCE | HUANG, GIGI GEORGIANA | 34d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17640889 | METHODS FOR ALLEVIATING PTERYGIUM-ASSOCIATED WORRY ABOUT EYE APPEARANCE | HUANG, GIGI GEORGIANA | 34d |
| 18307449 | EMULSION FORMULATIONS OF MULTIKINASE INHIBITORS | HUANG, GIGI GEORGIANA | — |
| Art Unit | Apps |
|---|---|
| 1613 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18307449 | EMULSION FORMULATIONS OF MULTIKINASE INHIBITORS | HUANG, GIGI GEORGIANA | 1613 | §103 | Final Rejection | — | Pending | Apr 26, 2023 |
| 17640889 | METHODS FOR ALLEVIATING PTERYGIUM-ASSOCIATED WORRY ABOUT EYE APPEARANCE | HUANG, GIGI GEORGIANA | 1613 | §103§112Other | Non-Final OA | 34d | Pending | Mar 07, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial